7H-dibenzo[b,d]azepin-7-one | 96794-10-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 7H-dibenzo[b,d]azepin-7-one
• 英文别名: dibenzo[b,d]azepin-7-one；dibenzo azepinone；7-Oxo-dibenzazepin；7-Oxo-dibenz[b,d]azepin；Benzo[d][1]benzazepin-7-one
• CAS: 96794-10-4
• 化学式: C₁₄H₉NO
• 分子量: 207.232
• InChiKey: IICVGZNCRBUCHY-UHFFFAOYSA-N

物化性质

• 沸点：
  420.0±28.0 °C(Predicted)
• 密度：
  1.18±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  7H-dibenzo[b,d]azepin-7-one 450.0 ℃ 、26.66 Pa 条件下， 反应 -6.0h， 生成 联苯烯 、 苯甲腈
  参考文献：
  名称：

  用MCM-41催化剂通过异相闪蒸热解一锅合成7H-二苯并[b，d] azepin-7-one。

  摘要：

  报道了2-（1H-1,2,3-苯并三唑-1-基）苯基乙酮（1）的均相和异相闪蒸热解（fvp）反应。用Al-MCM-41催化剂（M41S型中孔分子筛）进行多相反应。在这两种情况下，7H-二苯并[b，d] azepin-7-one（4）是主要产物。然而，在催化反应中，收率和选择性很高。还讨论了该反应的机理。

  DOI：

  10.1021/ol070690c
• 作为产物：
  描述：

  2-(benzotriazol-1-yl)acetophenone 在 barium tungstate 作用下， 以45%的产率得到7H-dibenzo[b,d]azepin-7-one
  参考文献：
  名称：

  Mixed Oxides as Highly Selective Catalysts for the Flash Pyrolysis of Phenacyl Benzotriazole: One-Pot Synthesis of Dibenzazepin-7-one

  摘要：

  The one-pot synthesis of dibenzo[b,d]azepin-7-one (3) was selectively achieved from 1-phenacyl-1,2,3-benzotriazole (1) using the catalytic flash vacuum pyrolysis (cfvp) methodology. Catalysts with the scheelite structure ABO(4) (A = Ca2+, Sr2+, Ba2+ and B = Mo6+, W6+) and fergusonite BiVO4 were explored in this new catalytic reaction. These oxides promoted high conversion of starting material at lower temperatures than those observed for noncatalytic reactions. The chemical nature of A and B cations in the scheelite structure showed a strong influence on the formation toward the desired azepinone. In addition, the catalyst's morphology had a significant influence on the course of the cfvp reaction.

  DOI：

  10.1021/cs3008335

文献信息

• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020045747A1

  公开（公告）日：2002-04-18

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• [EN] 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE - 3 - CARBOXYLIC ACID AMIDE DERIVATIVES AND RELATED COMPOUNDS AS BRADYKININ B1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES<br/>[FR] DERIVES AMIDES DE L'ACIDE CARBOXYLIQUE DE 4- BROMO - 5 - (2- CHLORO - BENZOYLAMINO) - 1H - PYRAZOLE 3 ET COMPOSES ASSOCIES EN TANT QU'ANTAGONISTES DE RECEPTEUR DE B1 DE LA BRADYKININE POUR LE TRAITEMENT DE MALADIES INFLAMMATOIRES
  申请人：ELAN PHARM INC

  公开号：WO2004098589A1

  公开（公告）日：2004-11-18

  Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.

  公开的是化合物I和II的结构式，它们是激肽酶B1受体拮抗剂，适用于治疗哺乳动物中由激肽酶B1受体介导的疾病，或缓解与疾病状况相关的不良症状。其中某些化合物表现出增强的效力，并且预计还将表现出延长作用的特性。
• PROCESS FOR PREPARATION OF ENANTIOMERICALLY PURE COMPOUNDS
  申请人：Hoffmann-Emery Fabienne

  公开号：US20080293933A1

  公开（公告）日：2008-11-27

  The invention relates to a process for the optical resolution of a dibenzo[b,d]azepinone derivative of formula II, wherein R 1 is hydrogen or halogen and R 2 is either C 1-4 -alkyl optionally substituted with C 3-7 -cycloalkyl or benzyl which is optionally substituted with C 1-4 -alkoxy, to obtain a (S)-7-amino-5H,7H-dibenzo[b,d]azepin-6-one of formula I, wherein R 1 is as in the compound of formula II. The (S)-7-amino-5H,7H-dibenzo[b,d]azepin-6-one of formula I can be used as a chiral building block for the preparation of malonamide derivatives which have the potential to act as γ-secretase inhibitors and therefore may be useful in the treatment of Alzheimer's disease and cancer.

  该发明涉及一种用于光学分辨二苯并[b,d]氮杂环己酮衍生物的过程，其化学式为II，其中R1为氢或卤素，R2为C1-4烷基，可选择性地取代为C3-7环烷基或苄基，苄基可选择性地取代为C1-4烷氧基，以获得化学式为I的(S)-7-氨基-5H,7H-二苯并[b,d]氮杂环己酮，其中R1如化合物II的情况。化学式为I的(S)-7-氨基-5H,7H-二苯并[b,d]氮杂环己酮可用作手性构建块，用于制备马隆酰胺衍生物，这些衍生物有潜力作为γ-分泌酶抑制剂，因此可能在治疗阿尔茨海默病和癌症方面有用。
• [EN] C-ABL TYROSINE KINASE INHIBITORY COMPOUND EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] COMPOSÉ INHIBITEUR DE TYROSINE KINASE C-ABL, MODES DE RÉALISATION, PROCÉDÉS DE FABRICATION ET D'UTILISATION ASSOCIÉS
  申请人：US HEALTH

  公开号：WO2019173761A1

  公开（公告）日：2019-09-12

  Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as "c-Abl"). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c- Abl inhibitory compound embodiments.

  本文披露了一种抑制c-Abl酪氨酸激酶（本文中也称为"c-Abl"）的化合物实施例。本文描述的这些化合物实施例是新颖的c-Abl抑制剂，可以结合到c-Abl的一个变构位点，并在各种途径中抑制其活性。这些化合物实施例还能够穿过血脑屏障，因此在抑制影响大脑途径和/或蛋白质的c-Abl活性方面是有用的。本文描述的这些化合物实施例是治疗涉及c-Abl的疾病的有效治疗剂，如癌症、运动神经元疾病和神经退行性疾病。本文还披露了制备和使用c-Abl抑制化合物实施例的方法实施例。
• [EN] PENTACYCLIC PYRIDOINDOLOBENZ[b,d]AZEPINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE PYRIDOINDOLOBENZ[B,D]AZÉPINES PENTACYCLIQUES ET LEURS UTILISATIONS
  申请人：DAYA DRUG DISCOVERIES INC

  公开号：WO2014137848A1

  公开（公告）日：2014-09-12

  The present invention discloses pyridoindolobenz[b,d]azepines compositions of Formula 1, wherein Y is a single bond or a double bond. A and B are independently -(CH2)n-; and 'n' varies from 0 to 3. R1 to R10 are various electron donating, electron withdrawing, hydrophilic, or lipophilic groups selected to optimize the physicochemical and biological properties of compounds of Formula I.

  本发明公开了式1的吡啶吲哌并苯[b,d]氮杂环化合物组合物，其中Y是单键或双键。A和B独立地为-(CH2)n-; 'n'的值在0至3之间变化。R1到R10是各种电子给予、电子提取、亲水性或亲脂性基团，选择这些基团以优化式I化合物的物理化学和生物学性质。